Corcept Therapeutics Incorporated (CORT) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Corcept Therapeutics Incorporated stock $50.04, price $72.77, that is 31.2% below the price, quality 73 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $16.53 – $123.57 · fair‑value band $29.46 – $81.80 · the $72.77 price screens above the $50.04 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Corcept Therapeutics in your weekly email
Every Wednesday you see whether Corcept Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
Show moreShow less
The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease.
The company was incorporated in 1998 and is headquartered in Redwood City, California.
Stock analysis
Corcept Therapeutics Incorporated (CORT) currently trades at $72.77, while our model-based Fair Value estimate is $50.04, 31% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $32.62 per share, and 0 of the 24 models we run sit above the $72.77 price.
Bear case: the Economic Profit group reads lowest at $6.80, and 24 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $29.46 (bear) to $81.80 (bull), the price of $72.77 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 73/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Corcept Therapeutics Incorporated reported revenue of $761M in FY2025 versus $366M in FY2021, a compound +20.1%/yr. Reported net income was $99.7M in FY2025, compounding −3.0%/yr from FY2021.
Key figures
Market cap $8.6B Mid · P/E ratio 60.6 · P/S ratio 8.94 · EPS (TTM) $1.20 · Net margin 16.8% · Return on equity 22.2% · Return on assets (EBIT) 17.5% (5-year average) · Operating margin 33.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 77 out of 100 (medium confidence).
What moves the price
The share trades about 41% below its 52-week high and 126% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −31%, CORT screens richer than that median.
Fair Value models
Bear$29.46Fair Value $50.04Bull$81.80
Price $72.77 · Downside -31.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($1.03 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 10 officers or directors sold shares worth $81.0M and none bought.
SaleSean MaduckOther11× since Dec 1, 2025: 275,955 shares, avg. $90.74$25.0MNov 3, 202610b5-1 plan
SaleRoberto Wandenkolk VieiraPresident, Oncology4× since Sep 2, 2026: 75,295 shares, avg. $108.00$8.1MNov 2, 202610b5-1 plan
SaleJames N WilsonDirector5× since Jun 16, 2026: 50,000 shares, avg. $101.69$5.1MOct 15, 202610b5-1 plan
SaleJoseph Douglas LyonOfficer5× since Dec 1, 2025: 31,540 shares, avg. $101.27$3.2MOct 2, 2026
SaleKimberly ParkDirector26,685 shares at $122.55$3.3MAug 26, 2026
SaleDavid L MahoneyDirector2× since Jun 17, 2026: 123,606 shares, avg. $112.80$13.9MAug 18, 2026
SaleGary Charles RobbChief Business Officer10,000 shares at $116.26$1.2MAug 17, 2026
SaleWilliam GuyerChief Development Officer12× since Nov 25, 2025: 184,500 shares, avg. $62.90$11.6MAug 10, 2026
SaleAtabak MokariChief Financial Officer4× since Jun 1, 2026: 200,000 shares, avg. $93.66$18.7MJul 30, 202610b5-1 plan
SaleJoseph K BelanoffChief Executive Officer, Director4× since Dec 1, 2025: 119,035 shares, avg. $62.18$7.4MJun 1, 202610b5-1 plan
Plus 1 more entries from the last 12 months.
Plus 39 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.91/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+12.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.6%
Start year 2020 (pandemic). Over 10 years: +31.2% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+51.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−0.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.5%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−0.5% vs 28.0%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.36% → 6%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes more growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+26.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+39.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +23.6% a year for the price and +36.7% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: High margins in a niche therapeutic area offer moderate moat potential, yet concentrated product risk and thin signals on durability remain the central weakness.
Main risk: Teva's generic version of Korlym, cleared after a federal appeals court ruling of non-infringement, could capture share and force lower prices or margins on Corcept's primary revenue source in Cushing's syndrome.
Bull case: Corcept could offset any Korlym erosion by accelerating adoption of its approved Lifyorli in platinum-resistant ovarian cancer and securing further relacorilant approvals through refined data submissions.
Bear case: If generics from Teva gain traction on Korlym while regulatory setbacks persist for additional relacorilant indications, Corcept's revenue base could shrink and its shift to oncology might stall amid ongoing legal costs.
Corcept has moved from its single-product Korlym base in Cushing's syndrome to an FDA-approved relacorilant for platinum-resistant ovarian cancer with supporting overall survival data. The shift opens a much larger addressable market yet keeps the company exposed to typical biotech risks around adoption, reimbursement and follow-on trials. Our models see the shares as overvalued. Will the oncology indication become the main growth engine or stay an add-on to the established metabolic business?
Compare Corcept Therapeutics Incorporated with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score73 · Top 25%
Fair Value upside−31.2% · Above median
Profitability
Return on equity (12 months)22.2% · Top 25%
Return on assets11.9% · Top 25%
Net margin (12 months)16.8% · Above median
Operating margin (12 months)33.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)64.0% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)60.6× · Priciest 25%
P/B13.30× · Priciest 25%
P/S (12 months)8.94× · Pricier than median
Price / free cash flow (fiscal year)60.8× · Pricier than median
EV/EBITDA75.1× · Priciest 25%
PEG0.81× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)89· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Corcept Therapeutics Incorporated (CORT) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $50.04 versus a price of $72.77, about 31% lower (overvalued).
What is the fair value of CORT?
Our model-based fair value for Corcept Therapeutics Incorporated is $50.04 (as of Nov 6, 2026), built from audited fundamentals. The current price: $72.77.
What is the quality score of CORT?
Corcept Therapeutics Incorporated has a Quality Score of 73/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Corcept Therapeutics Incorporated (CORT)?
Our model-based price target is the fair value of $50.04 (as of Nov 6, 2026) from 24 valuation models. Cautious scenario $29.46, optimistic scenario $81.80. It is a calculation from audited fundamentals, not an analyst target.
What is the Corcept Therapeutics Incorporated stock forecast for 2026?
Our models put fair value at $50.04, about 31% lower versus a price of $72.77 (overvalued). Cautious scenario $29.46, optimistic scenario $81.80. The calculation is refreshed regularly with new filings.
What is the revenue of Corcept Therapeutics Incorporated (CORT)?
Corcept Therapeutics Incorporated reported trailing-twelve-month revenue of about $964M (latest available figure, as of Nov 6, 2026).
What growth is priced into Corcept Therapeutics Incorporated (CORT)?
For today's price to be fair in a discounted-cash-flow model, Corcept Therapeutics Incorporated would have to grow free cash flow by +26.5 % per year for five years (discount rate 8.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +16.6 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of CORT use?
Our models discount Corcept Therapeutics Incorporated at 8.7 %: a base by market capitalisation (mid), damped by beta 0.56, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Corcept Therapeutics Incorporated that is +26.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.7 %) and the same formula as our fair value.
How much growth has Corcept Therapeutics Incorporated (CORT) delivered so far?
Over the past 5 years revenue at Corcept Therapeutics Incorporated grew +16.6 % a year. The price currently implies free-cash-flow growth of +26.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Corcept Therapeutics Incorporated (CORT) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Corcept Therapeutics Incorporated (+26.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Corcept Therapeutics Incorporated (CORT)?
The free-cash-flow yield on the price is 1.65 %: that much free cash flow Corcept Therapeutics Incorporated produces per unit of market value. When it exceeds the discount rate of our models (8.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Corcept Therapeutics Incorporated (CORT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Corcept Therapeutics Incorporated it is $50.04 per share (as of Nov 6, 2026), against a price of $72.77. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Corcept Therapeutics Incorporated stock overvalued or undervalued in 2026?
As of Nov 6, 2026, CORT trades above its calculated fair value: price $72.77, fair value $50.04, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CORT?
No. The price is what the market pays today ($72.77); the fair value is what the company's own numbers justify ($50.04). For Corcept Therapeutics Incorporated the two are $22.73 per share apart. That gap is exactly why we show both numbers side by side.
How much is Corcept Therapeutics Incorporated worth?
The market values Corcept Therapeutics Incorporated at about $8.6B (market capitalisation, as of Nov 6, 2026). Per share that is $72.77; our models calculate a fair value of $50.04 per share.
What do the bullish and bearish scenarios say about CORT?
Our models span a range for Corcept Therapeutics Incorporated: cautious scenario $29.46, base $50.04, optimistic $81.80 per share (as of Nov 6, 2026, price $72.77). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CORT?
Corcept Therapeutics Incorporated trades at a price-to-earnings ratio of 60.6 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $50.04 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings, FY2022, FY2025 ex one-offs: 26.5. Other multiples: PEG 0.8, P/B 13.3, P/S 8.9, EV/EBITDA 75.1.
What is the PEG ratio of CORT?
The PEG ratio of Corcept Therapeutics Incorporated is 0.81 (P/E divided by earnings growth, as of Nov 6, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Corcept Therapeutics Incorporated (CORT)?
Balance-sheet figures for Corcept Therapeutics Incorporated (as of Nov 6, 2026): return on equity 22.2%. They feed the Quality Score of 73/100, which measures business quality independently of the share price.
How far is CORT from its 52-week high?
Corcept Therapeutics Incorporated trades at $72.77, about 41% below its 52-week high of $123.57 and 126% above the low of $32.15 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $50.04 is for.
Which stocks are comparable to Corcept Therapeutics Incorporated?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Corcept Therapeutics Incorporated stock attractive at the current price?
The data as of Nov 6, 2026: price $72.77, calculated fair value $50.04 (−31%), Quality Score 73/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CORT calculated?
We run Corcept Therapeutics Incorporated through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $50.04 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Corcept Therapeutics Incorporated itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Corcept Therapeutics Incorporated (CORT)?
The closing price on Nov 6, 2026 was $72.77. Our model-based fair value is $50.04, about 31% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Corcept Therapeutics Incorporated right now?
The model range is unusually wide ($29.46 to $81.80). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (73/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Corcept Therapeutics Incorporated
How large is the market capitalisation of Corcept Therapeutics Incorporated (CORT)?
The market capitalisation of Corcept Therapeutics Incorporated is $8.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Corcept Therapeutics Incorporated (CORT)?
The price-to-sales ratio of Corcept Therapeutics Incorporated is 8.94 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Corcept Therapeutics Incorporated (CORT)?
Earnings per share at Corcept Therapeutics Incorporated are $1.20 (price ÷ EPS = P/E 60.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Corcept Therapeutics Incorporated (CORT)?
The net margin of Corcept Therapeutics Incorporated is 16.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Corcept Therapeutics Incorporated (CORT)?
The return on equity (ROE) of Corcept Therapeutics Incorporated is 22.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Corcept Therapeutics Incorporated (CORT)?
On an EBIT basis the return on assets of Corcept Therapeutics Incorporated is 17.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Corcept Therapeutics Incorporated (CORT)?
The operating margin of Corcept Therapeutics Incorporated is 33.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Corcept Therapeutics Incorporated (CORT)?
Revenue at Corcept Therapeutics Incorporated is growing +64.0% versus a year earlier (3y avg +23.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Corcept Therapeutics Incorporated (CORT)?
Earnings per share at Corcept Therapeutics Incorporated are growing +531% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Corcept Therapeutics Incorporated (CORT) hold?
Corcept Therapeutics Incorporated holds more cash than debt, $114M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Corcept Therapeutics Incorporated in the live analysis
One click puts Corcept Therapeutics Incorporated on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026